SAN DIEGO, Nov. 21 /PRNewswire/ -- ChemDiv Inc. and Avineuro Pharmaceuticals Inc. have extended the term of their research and development collaboration including formulation, safety and early clinical development studies in areas of neurodegenerative and psychiatric disorders. R&D services will be provided by Chemical Diversity Research Institute, ChemDiv's research subsidiary based in Moscow. The new agreement provides for research funding of clinical candidate compounds to POC. Avineuro is responsible for further clinical development and commercialization of drug candidates AVN101, AVN211, and additional compounds that may be nominated for development from the ongoing research and discovery under the agreement. In September, ChemDiv entered into an out-licensing and collaboration agreement with Avineuro to develop multiple compounds for Alzheimer Disease and schizophrenia. Under the agreement, Avineuro obtained exclusive worldwide rights to clinical development candidates AVN101, AVN211, and lead compounds in various stages of pre-clinical development. ChemDiv will provide pre-clinical development services to nominate additional backup leads and candidates for Avineuro.
About Avineuro Pharmaceuticals, Inc.:
Avineuro Pharmaceuticals, Inc. discovers and develops novel small
molecules for unmet medical needs in neurology and psychiatry. Founded in
August 2008 and headquartered in San Diego, California, Avineuro is managed by
seasoned professionals experienced in drug discovery and development. By
acquiring lead compounds through collaborations and partnerships, Avineuro
plans to develop novel products and extend the reach of marketed compounds for
indications with a significant commercial potential. Avineuro emphasizes a
rational approach that combines modern medicinal chemistry with streamlined
pre-clinical and clinical development studies, thus allowing a fast transition
to proof-of-concept product candida
|SOURCE ChemDiv, Inc.; Avineuro Pharmaceuticals|
Copyright©2008 PR Newswire.
All rights reserved